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The term paradigm was introduced into science and philosophy by Thomas Kuhn in 1962 to refer to the set of concepts that define particut
lar scientific thinking during a given period of time.1 
The term refers to the predominant worldview in a part
ticular realm of human thought. Kuhn hypothesized 
that paradigm shifts occur when new and more accurate 
theories (which represent approximations of the undert
standing about a topic) replace earlier, less comprehent
sive theories. 
The medical intervention known as blood transt
fusion is associated with both beneficial effects and 
adverse events in recipients. Over the past 100 years, 
transfusion medicine has experienced many challenging 
periods resulting in the introduction of improvements 
in technology to increase the safety of allogeneic blood 
transfusion. There have thus been six major paradigt
matic shifts associated with transfusion medicine scit
ence and technology (Table 1). Conceptual and technot
logical developments in transfusion medicine are thus 
ongoing processes and more paradigm shifts are to be 
expected in the future. These may include modification 
of the red blood cell (RBC) surface to reduce antigenict
ity11,12 and the development of novel ways to produce 
the improvement of transfusion medicine technology is an ongoing process primarily directed at increas-
ing the safety of allogeneic blood component transfusions for recipients. over the years, relatively little 
attention had been paid to the leukocytes present in the various blood components. the availability of 
leukocyte removal (leukoreduction) techniques for blood components is associated with a considerable 
improvement in various clinical outcomes. these include a reduction in the frequency and severity of fe-
brile transfusion reactions, reduced cytomegalovirus transfusion-transmission risk, the reduced incidence 
of alloimmune platelet refractoriness, a possible reduction in the risk of transfusion-associated variant 
creutzfeldt-Jakob disease transmission, as well as reducing the overall risk of both recipient mortality and 
organ dysfunction, particularly in cardiac surgery patients and possibly in other categories of patients. 
internationally, 19 countries have implemented universal leukocyte reduction (ulr) as part of their blood 
safety policy. the main reason for not implementing ulr in those countries that have not appears to be 
primarily concerns over costs. nonetheless, the available international experience supports the concept 
that ulr is a process that results in improved safety of allogeneic blood components.
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blood products in vitro (for example, RBCs).13 
Considerable progress has been made over the past 
two decades to reduce the risk of the adverse events 
associated with the transfusion of blood components. 
However, significant transfusiontassociated morbidity 
and mortality remain a problem.14t17 Recent data from 
various hemovigilance systems worldwide showed that 
the most common causes of transfusiontassociated 
mortality include transfusiontrelated acute lung injury 
(TRALI), ABO hemolytic transfusion events, and bact
terial sepsis associated with the transfusion of bacteria 
present in contaminated blood components (Tables 
2, 3). The number of transfusiontassociated mortalt
ity cases reported annually increased considerably over 
the past 30 years, which is probably mostly related to 
increased recognition of such events as being transfut
siontassociated. As can be seen in both Tables 2 and 3, 
TRALI has become the most commonly reported cause 
of transfusiontassociated mortality.
The transfusion transmission risk of many pathot
gens has been greatly reduced by the development of int
creasingly sensitive screening methods; however, transt
fusionttransmitted infections still occur. Transfusiont
related infections continue to be reported as tests for 
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many known pathogens are not yet available or not bet
ing used.18t22 In addition, the ongoing emergence of new 
agents demonstrates that potential threats to the blood 
supply will continue to emerge worldwide.
Potential adverse effects associated with the transfut
sion of blood components containing donor leukocytes 
and their soluble biological mediators, such as cytot
kines, are known to have a number of biologic effects 
associated with transfusion.23 Leukocytes with their 
specific allogenic structure (the HLA class I and class II 
Table 1. Major paradigm shifts in transfusion medicine.
Early 1900
karl landsteiner discovers the AbO blood groups and humoral immunity becomes the main paradigm explaining 
the effects of allogeneic transfusion.2 
1940 edwin Cohn develops cold ethanol fractionation, the process of breaking down plasma into protein components 
and products.3
1950
Carl walter and w.p. Murphy introduce the plastic bag for blood collection and component preparation, 
replacing breakable glass bottles with durable plastic bags and most importantly allowing sterile blood 
component preparation.4,5
1960 to 1980
post transfusion viral infections became a major concern affecting the blood recipient, resulting in the 
development and implementation of effective screening methods to reduce pathogen transmission.6,7
1990
 leukocyte reduction of blood components are shown to be associated with improved clinical outcome, which 
lead to the implementation of ulr in many countries.8  
1995  to  2010
Development of pathogen inactivation (reduction) technology to reduce the risk of pathogen transmission by 
blood components. This will lead to the development of pathogen inactivation technologies to treat the various 
cellular blood components to further improve blood safety.9,10
ulr = universal leukoreduction
Table 2.  Annual number of transfusion-associated cases reported to the uS FDA over the three decades from 1976 to 2005.14
Period Total annual rate ABO/HTR TRALI Bacterial sepsis Others*
1976 - 1985 25.6 15.8 3.9 2.6 3.3
1986 - 1995 30.3 15.1 4.4 4.9 5.9
1996 - 2000 62.6 11.2 nA nA nA
2001 - 2003 88.3 12.6 14.4 12.5 48.8
2004 82.0 7.0 21.0 6.0 48.0
2005 105.0 5.0 30.0 9.0 61.0
*includes graft-versus-host disease, delayed hemolytic transfusion reactions, transfusion transmitted infections other than bacterial sepsis, anaphylaxis, post-transfusion purpura, 
transfusion-associated circulatory overload, and others. AbO/HTr=AbO/ hemolytic transfusion reaction, TrAli=transfusion-related acute lung injury, nA = data not available.
Table 3. Transfusion-associated causes of mortality reported to uk Serious Hazards of Transfusion (SHOT) program (1996-2004).15
Attributed cause of mortality Definite Probable Possible Total
Transfusion related acute lung injury 8 5 23 36
incorrect blood component 
transfused† 6 3 11 20
Graft-versus-host disease 13 0 0 13
Acute transfusion reaction‡ 2 3 7 12
Transfusion-transmitted infection 9 0 0 9
Delayed transfusion reaction 6 1 1 8
post-transfusion purpura 1 0 1 2
Total 45 12 43 100
†patient transfused with component or product that did not meet the appropriate requirement, or was intended for another patient. ‡Acute transfusion reaction occurring within 24 
hours following a transfusion, excluding that due to ibCT.
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antigens on their surface) appear to be the main targets 
of a recipient’s immune system. In addition, some vit
ruses can be transmitted as they exist within leukocytes 
(i.e. CMV, HHVt8, and HTLVtI/II). Another, not so 
well characterized effect of transfused leukocytes, is the 
potential modulating influence on the recipient’s imt
mune system.2  Leukocyte reduction is typically defined 
as a blood processing step for reducing the leukocyte 
content of whole blood, RBCs, or platelet units down 
to 5×106 (1×106 in Europe) residual WBCs per unit 
of component. Universal leukocyte reduction (ULR) is 
the routine application of the bloodtprocessing step to 
all units of whole blood, RBCs, and platelets prior to 
storage in a country or in a blood transfusion service.25 
 To attempt to prevent the adverse effects of the leut
kocytes contained in blood components, several metht
ods have been developed to remove leukocytes from the 
various blood components.25,26 Leukocyte reduction 
procedures can be performed either pretstorage at the 
blood collection facility, or posttstorage either at the 
hospital transfusion service or at the patient’s bedside 
just prior to transfusion.27 Pretstorage leukocyte ret
duction of cellular blood components removes donor 
WBCs before they undergo apoptosis or necrosis and 
before they release breakdown products or cytokines.
The removal of leukocytes from various blood comt
ponents can be associated with several improved clinical 
outcomes (Table 4). These outcomes, subdivided as to 
whether each benefit has been proven by evidencetbased 
guidelines to be clinically relevant, likely to be clinically 
relevant, and of unproven benefit (i.e. those that can be 
considered only of theoretical relevance).8
The major disadvantages associated with leukocyte 
Table 4.  putative clinical benefits of leukocyte reduction, subdivided as to whether the 
benefit has been proven by evidence-based guidelines to be relevant clinically, likely 
relevant clinically, or clinical relevance is unproven.8
Proven relevant clinically:
− reduced frequency and severity of nHFTrs;
− reduced risk of CMV transmission;
− reduced risk of HlA-alloimmunization and platelet refractoriness.
− reduced mortality and organ dysfunction in cardiovascular surgery patients.
Likely clinically relevant:
− reduced infectious risk associated with immunomodulation (TriM);
− reduced direct risk of transfusion-transmission bacteria.
Unproven clinically:
 − Avoidance of vCJD transmission.
 − Avoidance of HTlV i/ii, ebV etc.
 − reduced risk of GVHD.
 − reduced risk of TrAli.
nHFTrs, non-hemolytic febrile transfusion reactions; CMV, cytomegalovirus; vCJD, variant Creutzfeldt-Jacob disease; 
GVHD, graft-versus-host disease; TrAli, transfusion-associated acute lung injury.
reduction are cost and logistics.28 The report from the 
Canadian Coordinating Office for Health Technology 
Assessment (CCOHTA) published in 1998 concluded 
that ULR of both platelets and RBCs would add a sigt
nificant expense to the Canadian health care system, 
but that leukocyte reduction of all transfused platelets 
might be cost effective.24 As a result, leukocyte reduct
tion of all platelets was introduced in Canada during 
the first quarter of 1998. Leukocyte reduction of RBCs 
was only introduced subsequently and ULR for all 
blood products was fully implemented in Canada in 
July 1999.29
There is some loss in product potency associated 
with leukoreduction technology, although, at the prest
ent time, for RBCs this is unlikely to cause an increased 
demand for RBC transfusions because of the concurt
rent increase in the volume of whole blood collections 
that offsets this loss in product potency. With regard 
to the loss in platelet potency, there is considerable unt
certainty about the proper therapeutic dose of platelets, 
such that a 10% to 15% quantitative reduction is unt
likely to be noticeable clinically. As in the case of RBCs, 
the increase in whole blood collections will also likely 
increase platelet potency of whole bloodtderived platet
lets by negating the 11% filtration effect.30
 Adverse effects associated with the use of leukocyte 
reduction filters have been reported.31t33 The reported 
severe hypotensive reactions to leukocyte reduced 
blood components have been associated mainly with 
the transfusion of blood components filtered at the bedt
side.34 These reactions are attributed to the generation 
of bradykinin and possibly other vasodilators, as dot
nor plasma passes over the filter media.35,36 Bradykinin 
generated during filtration has a short halftlife and is 
therefore biologically active only on direct intravenous 
administration. Blood components that are leukocyte 
reduced by pretstorage filtration appear not to cause 
hypotensive reactions and current knowledge indicates 
that transfusion of these blood components is generally 
free from complications associated with the use of leut
kocyte reduction filters.29 However, recent reports show 
that hypotensive reactions can occur even with the 
prestorage leukoreduction of blood products in which 
a defect in the metabolism of kinins may be a risk fact
tor.37 
 The implementation of ULR has created some new 
requirements relating to the need to standardize and 
to quality control the whole process.38 In our opinion 
the associated clinical benefits of leukocyte reduction 
nonetheless far overweigh the adverse features, and in 
the absence of considerations of cost, most transfusion 
medicine professionals would readily endorse a policy 
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Table 5. levels of scientific evidence that can be used to evaluate the efficacy of various transfusion medicine interventions (modified 
from Sackett).40
Level Scientific Evidence
1 Data from rCTs that are sufficiently large to give clear cut results, with only a small risk of an error. This level of evidence includes meta-analysis from such rCTs. 
2 Data from small rCTs that give uncertain results and that may have a moderate to high risk of error. This level of evidence includes meta-analysis from such rCTs.
3 nonrandomized cohort observational studies that use concurrent cohort data.
4 nonrandomized cohort observational studies that use historical cohort data.
5 Case series that use data from uncontrolled observations; or that represent unsubstantiated “expert” opinion.
      
to implement ULR by pretstorage filtration. Others 
argue that in the absence of adequate data suggesting 
universal benefit the technology should be applied set
lectively only to those patients who will clearly benefit 
from this intervention.39
In the opinion of the authors, implementation of 
ULR will improve transfusion safety, which should ext
tend to all patients receiving blood components at the 
very least for the proven benefits of this intervention. 
Although patients who have not had a febrile nonthet
molytic transfusion reaction (FNHTRs), who are not 
receiving longtterm platelet transfusions, and are not 
at risk of developing symptomatic CMV disease may 
derive no immediate benefit from prestorage leukocyte 
reduction, it is possible that they may accrue tangible 
benefits in the future. There are also cost savings in ret
sources, time and effort associated with improvements 
in the efficiency of the transfusion service and nursing 
personnel, which will further reduce the net community 
cost. 
The current practice of transfusion in Saudi Arabia 
and other countries around the world is selective leukot
cyte reduction. This review will thus present an upttot
date review of the clinical issues associated with leukot
reduction and the level of evidence indicating the efficat
cy, the current international status and the international 
experience, that we hope will influence the decision to 
implement ULR.
Evidence-based clinical efficacy of leukoreduc-
tion 
Evidencetbased medicine has been defined as the intet
gration of best research evidence with clinical expertise 
and patient values. Various classifications of the differt
ent types of scientific evidence available, to establish 
the efficacy of a particular intervention, have been prot
posed. Table 5 provides such a scheme for assessing the 
levels of medical and/or scientific evidence and is based 
on the various publications of Sackett and colleagues.40 
Many studies have been done to evaluate the efficacy of 
leukocyte reduction to prevent or reduce adverse effects 
caused by leukocytes present in blood components. The 
following sections review the evidence for various clinit
cal outcomes.
Non-hemolytic febrile transfusion reactions 
(NHfTR)
Historically, NHFTRs were thought to be associated 
with the presence in the recipient of antibodies to transt
fused allogeneic leukocytes. NHFTRs, the most comt
mon adverse effect of blood transfusions, are thought 
to be clinical manifestations of allotimmunization.41 
The minimum number and type of WBCs needed to 
generate a postttransfusion NHFTR in an alloimmut
nized recipient of blood components remains unclear.42 
Over the past decade, however, it has been established 
that most NHFTRs are due to cytokines present in the 
transfused blood components, having been elaborated 
during storage by the leukocytes.43
Many studies make the point that the timing of filt
tration is important for reducing the rate of NHFTRs. 
The age of the blood component is also an accepted risk 
factor. The older the component is, the greater the liket
lihood of an adverse reaction. This is particularly the 
case for platelet concentrates, which are stored at higher 
temperatures (22±2°C) than RBC units. Thus, a more 
obvious cause for a transfusion reaction than the numt
ber of remaining leukocytes was postulated.41,44,45
 Since older blood components have greater amounts 
of cytokines, the accumulation of soluble cytokines ret
leased from leukocytes during storage may be the explat
nation for the higher rate of NHFTRs.44,46t48 It seemed 
reasonable therefore that pretstorage of blood compot
nents would significantly reduce cytokine accumulat
tion during storage. Some clinical trials (not prospect
tive, randomized controlled trials) have demonstrated 
such effects of pretstorage filtration for RBCs49 even 
in previously alloimmunized patients.47 Many studies 
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Table 6.  incidence of non-hemolytic febrile transfusion reaction (per transfusion, excluding allergic and other reaction) (modified from 
CCOHTA).26
Pre-storage filtration Post-storage filtration No filtration
Platelets RBC Platelets RBC Platelets RBC
Federowicz  et al (1996)44 1.7%59/3405
1.1%
60/5412 nA
2.2%
139/6447 nA nA
Dzieczkowski et al (1995)49+ 1.6%82/5197 nA nA
2.2%
152/7080 nA nA
Heddle et al (1993)41++ nA nA 28%7/25 nA
37.5%
12/32 nA
Muir et al (1994)47+++ 0.9%2/223 nA
5%
14/280
0.8%
4/467 nA nA
+=apheresis platelets, FnHTr only; ++=pooled platelets, all reactions; +++=sensitized hematological patients, apheresis platelets. nA=not available
Table 7. reports describing non-hemolytic febrile transfusion 
reactions (nHFTr) rate reduction associated with the pre-stage 
leukoreduction (lr) of rbCs and platelets.8
For RBCs NHFTR rate reduction associated with LR
paglino et al50 0.34% to 0.18%
yazer et al51 0.33% to 0.19%
king et al52 0.37% to 0.19%
For Platelets
Heddle et al53 21.3% to 12.3%a
4.1% to 1.6%b
paglino et al50 2.18% to 0.11%
yazer et al51 0.45% to 0.11%
*Comparing nHFTr rate reduction of platelets from which in supernatant plasma was 
removed with that seen with pre-storage lr platelets. aAll nHFTr, bSevere nHFTr.
published after 1990 have addressed the incidence of 
febrile reactions in the context of leukocyte filtration 
(Table 6).26 All studies achieved a level of leukoreduct
tion of <5×106 leukocytes in the transfused blood comt
ponent.26
Until recently the role of leukoreduction in ameliot
rating the rate of NHFTRs had not been clearly estabt
lished. Several recent publications show clearly that leut
koreduction is associated with a significant reduction 
in the NHFTR rate (level 1 evidence) (Table 7).8 The 
NHFTR rate following RBC transfusion was shown 
to be reduced by approximately 50%, from 0.35% to 
0.18%.50t52 Similarly, the pretstorage leukoreduction of 
platelets, which is generally associated with an approxit
mate frequency of a 30% rate of NHFTRs, has been 
shown to be reduced significantly by transfusing pret
storage leukocyte reduced platelets.50,51,53
Pathogen transmission
Viruses. Leukoreduction is a known effective strategy 
for reducing the risk of the transmission of celltassocit
ated viruses. The most prominent among these are the 
herpes viruses, particularly CMV, also known as hut
man herpes virus (HHV) 5.54t60 CMV is transmitted 
by the leukocytes present in transfused blood compot
nents. To acquire CMV from a blood donor, a blood 
transfusion recipient must be exposed to donor WBCs 
that are latently infected with CMV. CMV then must 
be reactivated and the cell must survive long enough in 
the host to release infectious virus particles.61 Several 
patient populations are at risk for serious morbidity as 
a result of transfusiontassociated CMV infection (TAt
CMV), including low birth weight infants, some oncolt
ogy patients, allogeneic bone marrow transplant recipit
ents, but most particularly immunosuppressed patients. 
Early studies of TAtCMV indicate that the prevalence 
of postttransfusion CMV, without employing any pret
vention technology, may be as high as 30% per patient, 
depending upon the frequency of allogeneic blood comt
ponent transfusion.62 CMVtseronegative cellular blood 
components have been the standard approach provided 
to CMVtseronegative patient populations at high risk 
for significant morbidity for primary CMV infections.63 
However, the increasing number of immunosuppressed 
patients who might benefit from receipt of such compot
nents, the high prevalence of CMV antibody in some 
blood donor populations, and the logistics of maintaint
ing multiple inventories of blood components have led 
to the exploration of pretstorage leukoreduction as an 
alternative strategy for the provision of “CMVtsafe” 
blood components.57 The American Association of 
Blood Banks (AABB) has thus suggested that residual 
leukocyte levels less than 5×106 make a blood compot
nent “CMVtsafe”.64
It has been shown that the use of CMV seronegative 
reviewuniVerSAl leukOreDuCTiOn
Hematol Oncol Stem Cell Ther 1(2)     April 2008 hemoncstem.edmgr.com 111
allogenic transfusions in these patients will reduce this 
postttransfusion CMV risk to approximately 1.3%.58 
In comparison, a recent study has shown that the use 
of pretstorage leukoreduced RBCs or platelet transfut
sions can reduce the risk of postttransfusion CMV to 
approximately 2.5%.65 Over the years there have been 
a large number of studies examining strategies to pret
vent TAtCMV. Interpretation of some of these studies 
is difficult as many were not randomized, failed to use 
a control group, used historical controls, or were retrot
spective.57
Nonetheless, the balance of the evidence from the 
available clinical studies suggests that acceptable CMV 
safety can be achieved by pretstorage leukoreduction. 
Although it is likely that leukoreduced blood compot
nents are effective in reducing the risk of TAtCMV, 
there is insufficient evidence at this time to firmly rect
ommend the discontinuation of CMV testing even in 
the face of ULR.66 Considerable debate thus exists as 
to whether leukoreduction and the use of serologically 
negative CMV allogenic transfusion can be considered 
equivalent. A recent (2001) Canadian consensus cont
ference that has examined this issue in detail recomt
mended that hightrisk patients (i.e. allogenenic bone 
marrow transplant patients) receive leukoreduced blood 
products that are also seronegative for CMV.61
A recent study provides strong evidence (level 2 
evidence) that human herpes virus 8 (HHVt8) can be 
transmitted by allogeneic transfusion, particularly in 
high prevalence geographic regions.67 Based on the ext
perience with CMV, it is likely that pretstorage leukot
cyte reduction may prevent the transmission of HHVt
8 due to its WBCs associated nature. HHVt8 can cause 
a lifelong infection, with periodic reactivations, during 
which virus may circulate in peripheral blood WBCs 
and be transmissible through transfusion (level 5 evit
dence).68
For other viruses such as EpsteintBarr virus (EBV), 
human Ttcell lymphotrophic virus type I and II (HTLV 
I and II), no conclusive studies exist that demonstrate a 
similar efficacy of virus removal by leukoreduction as 
seen for CMV. Some experimental in vitro studies indit
cate a significant reduction of HTLV I virus from blood 
components by pretstorage leukoreduction but the pret
vention of clinical HTLV I infections with leukoreduct
tion in humans has not been proven. 69 Nonetheless, it 
is reasonable to assume that leukoreduction adds more 
safety to transfusion of blood components, since not 
all HTLV I infected donors express HTLV I antibodt
ies.70
Bacterial/protozoal infections. Bacterial contaminat
tion of blood components can result in a severe comt
plication of allogeneic blood transfusion in recipients. 
The risk of contaminated pooled platelet transfusion 
has been estimated to be as high as 2% (asymptomatic 
cases) since platelet concentrates are stored at room 
temperature (a temperature that facilitates bacterial 
growth) to preserve their viability and function.71t73 
Asymptomatic bacteremias and/or infections in a dot
nor and the ability of Yersinia enterocolitica to grow at 
low temperatures in an irontrich environment such as 
in stored RBC components makes Y entercolitica the 
most commonly encountered serious bacterial contamit
nant associated with RBC transfusion.74,75 Several studt
ies have demonstrated that the bacterial overgrowth of 
blood components by Y enterocolitica inoculated into 
blood components under experimental conditions is dit
minished or prevented by pretstorage leukoreduction, 
after a room temperature holding period.75,76 One way of 
reducing the risk of bacterial contamination in platelet 
concentrates is to reduce the level of leukocytes present. 
Filtration to remove leukocytes does not prevent bactet
rial growth, although it can reduce the level of bacterial 
contamination for some organisms. This process is not 
effective against some species of bacteria (for example, S 
epidermidis). This method, therefore, does not provide 
full protection against the risk of bacterial contaminat
tion, but has been shown to significantly reduce the risk 
of transfusiontassociated sepsis.77
The mechanisms by which leukoreduction removes 
bacteria are complex and several possibilities have been 
proposed, based on experimental data. First, bacteria 
are phagocyted during the proposed 8thour storage of 
blood at ambient temperatures and then removed with 
the leukocytes upon leukoreduction. Secondly, bacteria 
are adsorbed directly by the filter matrix or indirectly 
by binding to leukocytes and platelets or on activated 
complement components, which are removed by negat
tively charged filters.78 
Recent data from the Hemovigilance Network in 
France clearly indicates that the bacterial sepsis rate, as 
the percentage of all transfusion event rates, was signifit
cantly reduced (1.7% versus 3.8%) following the implet
mentation of ULR in France compared with before the 
implementation of ULR (Table 8).79 Of particular relt
evance is the fact that 1 in 3000 cellular blood compot
nents have been shown to contain bacteria.77
The risk of the transmission of Trypanosoma cruzi, 
the causative agent of Chagas’ disease, which is common 
in South America, but rare in other parts of the world, 
was shown to be decreased by leukoreduction, in an ext
perimental study in susceptible mice.80
Variant CrutzfeldtrJacob Disease transmission (vCJD). 
vCJD is a major concern of the transfusion medicine 
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Table 8. Occurrence of transfusion incident report (Tir) before and after implementation of universal leukocyte reduction in France.79
Before universal WBC 
reduction
After universal WBC 
reduction
Number % Number % Variation P value†
rbCs transfused 3 124 649 3 053 807 before/After (%)
HlA antibodies and nHFTr 112 6 33 2.3 -71 <.001
isolated nHFTr 615 32.9 363 25.8 -41 <.001
bacterial contamination 71 3.8 24 1.7 -66 <.001
Anaphylactoid 266 14.2 224 15.9 -16 .10
Hemolytic reactions (excluding 
AbO & D) 26 1.4 23 1.6 -12 .73
D incompatibility 12 0.6 11 0.8 -8 .88
AbO incompatibility 30 1.6 33 2.3 10 .64
Analysis of rbCs transfusion 18 months before and after implementation of universal wbC reduction shows as expected no significant impact on anaphylactoid reactions, AbO 
and D incompatibility and hemolytic reactions duo to other rbC antibodies. Conversely, there is dramatic reduction of Tirs related to HlA immunization, non-hemolytic febrile 
transfusion reactions (nHFTr) and bacterial contamination. †Comparison of rates (i.e. 1408/3 053 087 vs. 1872/3 124 649) using the chi–square test.
community, because infectivity can be detected in the 
lymphoreticular system as well as in blood.81 Evidence 
from an immunodeficient animal model of scrapie sugt
gests that host lymphocytes and/or follicular dendritic 
cells play a role in peripheral neuroinvasions.82,83 The 
abnormal prion protein PrPSc of vCJD has been det
tected in lymph nodes, tonsillar tissue, spleen and the 
appendix in clinical cases of vCJD.84 Animal studies 
have shown that B lymphocytes might play a key role 
in disease transmission.85 In several countries, part
ticularly in western Europe, ULR was instituted over 
the past 6 years in an attempt to reduce the theoretit
cal risk of vCJD transmission via transfusion of allot
geneic blood and blood components.86,87 Four cases of 
probable transfusion transmission of vCJD infection 
have recently been diagnosed in patients in the United 
Kingdom. All four cases had received transfusions of 
nontleukoreduced RBCs between 1996 and 1999 from 
donors who developed symptoms of vCJD after blood 
donation. These four cases of vCJD infection associated 
with blood transfusion increases the level of concern 
about the possible risk of vCJD transmission between 
humans by blood transfusion, although much remains 
unknown. This concern reinforces the importance of 
the existing precautions that have been introduced to 
reduce the risk of transmission of vCJD infection by 
blood and blood components.88 Blood screening assays 
are currently under development but are not yet ready 
for application.89 A recent study by Gregory et al, in a 
hamster model of bloodtborn transmissible spongiform 
encephalopathy (TSE) transmission, showed that filtrat
tion leukoreduction was associated with a reduced risk 
of TSE infection (from 48.1% to 31.5%).90 The authors 
of this study showed that filtration leukoreduction was 
associated with reduced TSE infectivity, but that this 
intervention was not sufficient to remove all TSE int
fectivity.91 Specific prion reduction filters for RBCs oft
fer the possibility of a further substantial reduction in 
vCJD infectivity and in the overall risk of vCJD transt
mission. However, concerns persist about how best to 
assess the efficacy of these technologies, since current 
assays are not sufficiently sensitive to detect infectivity 
in the blood of patients with clinical vCJD.92 
Alloimmunization and platelet refractoriness 
Alloimmunization is defined as a recipient immune 
response against antigens on tissue from a genetically 
dissimilar donor. The direct allotrecognition pathway 
occurs when recipient Tthelper cells directly interact 
with class II molecules encoded by the major histocomt
patibility complex (MHC) on donor antigentpresentt
ing cells (APCs). This pathway is the strongest known 
stimulator of immunity and the one targeted for ret
moval by leukoreduction strategies.93 The reduction in 
alloimmunization is a well documented beneficial effect 
of using leukoreduced blood component transfusions, 
and is especially important for repeatedly transfused 
patients and transplant recipients.93t98 Table 9 provides 
a cumulative metatanalysis of seven randomized, cont
trolled trials which clearly showed that the relative risk 
of HLA alloimmunization can be reduced considerably 
through the use of leukoreduced blood components 
(level 1 evidence). In the years 1983 to 1995 there were 
seven reports whose cumulative relative risk reduction 
with the use of leukoreduced allogenic blood compot
nents was 0.32, with 95% confidence intervals of 0.18 
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Table 9. Cumulative meta-analysis of randomized, controlled trials on the efficacy of leukoreduction in preventing HlA 
alloimmunization.99
Study Publication Year Cumulative sample size (study n)
Cumulative relative risk (RR) of HLA 
alloimmunization (95% Confidence intervals)
Schiffer et al100 1983 56 (56) 0.35 (0.10–0.16)
Sniecinski et al95 1988 96 (40) 0.32 (0.17–0.60)
Andreu et al96 1988 165 (69) 0.26 (0.16–0.49)
kooy et al101 1991 218 (53) 0.21 (0.12–0.35)
Oksanen et al102 1991 249 (31) 0.23 (0.13–0.38)
williamson et al103 1994 372 (123) 0.27 (0.16–0.46)
Sintnicolas et al104 1995 418 (46) 0.32 (0.18–0.56)
TrAp105 1997 818 (400) 0.30 (0.20–0.46)
to 0.56. These seven studies involved a total of only 418 
patients.8 In 1997, the TRAP study which examined 
the relative risk of HLA alloimmunization and platelet 
refractoriness in 400 patients provided level 1 evidence 
(a large randomized controlled trial) that the relative 
risk of HLA alloimmunization and platelet refractorit
ness with the use of leukoreduced blood components 
was statistically significant.99 The cumulative relative 
risk reduction of HLA immunization for all the pubt
lished studies, following the use of leukoreduced blood 
components, was recently estimated to be 0.30 (95% 
confidence intervals; 0.20 to 0.46).99 
A recent retrospective analysis of 13 902 platelet 
transfusions in 617 Canadian patients undergoing chet
motherapy for acute leukemia or stem cell transplantat
tion before (n=315) and after (n=302) the introduction 
of ULR showed a significant reduction in alloimmunit
zation (19% to 7%, P<.001) and in alloimmune platelet 
refractoriness (14% to 4%, P<.001). Alloimmunization 
and alloimmune refractoriness in 318 patients who were 
previously pregnant and/or transfused were also ret
duced after ULR (P=.23 and P=.005, respectively).106
Transfusion-related immunomodulation (TRIM) 
Most animal studies using whole blood transfusion 
have found immunosuppressivetlike responses in ret
cipients, primarily due to the leukocyte content of 
the donor blood.107 Moreover, evidence from a variety 
of sources indicates that allogenic blood transfusion 
(ABT) enhances the survival of renal allografts,108 and 
may increase the recurrence rate of resected malignant
cies,109 increase the incidence of postoperative bacterial 
infections,110t112 reduce the recurrence rate of Crohn’s 
disease,113 and reduce the risk of recurrent spontaneous 
abortion.114 This clinical syndrome, whose mechanisms 
still remain to be defined, has been referred to in the 
transfusion medicine literature as transfusiontrelated 
immunomodulation (TRIM).115
TRIM and surgery. The value of leukoreduction for 
preventing postoperative complications in patients unt
dergoing surgery has been investigated in many obsert
vational studies as well as in 12 randomized controlled 
trials, which were recently the subject of a metatanalysis 
that looked at the association between allogenic blood 
transfusion and postoperative infection.110t112,116t124,125 
The hypothesis of homogeneity was rejected across the 
12 trials (P<.01 for the Qttest statistic). When the ret
sults were combined under conditions of heterogenet
ity, the effect of the WBCtcontaining allogenic blood 
transfusion on postoperative infection did not quite 
attain statistical significance (summary OR=1.24; 95% 
CI, 0·98t1·56; P>.05). Four of these trials showed an 
increased association between allogenic blood transfut
sion and postoperative infection, but the others did not 
(Figure 1).116,120,122,123 One possible explanation for the 
lack of consistency among the trials is that the TRIM 
effect may in fact be quite small (i.e. less than 10%).8 
Vamvakas and Blajchman have postulated that to det
tect a 5% to 10% reduction in the risk of postoperative 
infection, a randomized trial enrolling 10 000 to 20 000 
subjects would be required. Such a study has not been 
done and is unlikely to be done in the foreseeable fut
ture.126 
There is also evidence that the use of leukoreduced 
blood components is associated with improvement in 
morbidity and mortality in cardiac surgery.110,119,121t123t
125 A randomized trial involving a large series of patients 
in whom the mortality rate was 50% less in patients ret
ceiving leukoreduced blood also reported a significantly 
lower postoperative infection rate.110 The findings of 
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Figure 1. randomized controlled trials (rCTs) investigating the association of white blood cell (wbC)-containing allogeneic blood 
transfusion (AbT) with postoperative  infection.125 For each rCT, the figure shows the odds ratio (Or) of postoperative infection in 
recipients of non-wbC-reduced vs. wbC-reduced allogeneic red blood cells (rbCs) or whole blood, as calculated from an intention-
to-treat analysis. each Or is surrounded by its 95% confidence interval (Ci). if the 95% Ci of the Or includes the null value of 1, the 
immunomodulatory (TriM) effect is not statistically significant (P>·05). A deleterious effect of AbT is indicated by an Or >1, provided 
that the associated 95% Ci does not include the null value of 1.
this large study suggest that leukoreduction should 
be applied for all patients undergoing cardiac surgery 
in order to improve patient outcome. Figure 2 shows 
the summary odds ratio of shorttterm mortality in ret
cipients of nontleukocyte reduced versus leukocytetret
duced allogeneic RBCs, from 5 randomized, controlled 
trials conducted in cardiac surgery. When the 5 trials 
were studied in a metatanalysis, WBCtcontaining allot
geneic blood transfusion was associated with a 72% int
crease in postoperative mortality (summary OR=0.99; 
95% CI, 0.73t1.33; P>.05) compared to patients receivt
ing leukoreduced allogeneic blood.127 
A prospective randomized study by Alexiou et al 
reported that leukoreduction reduces the numbers 
of circulating activated leukocytes and pulmonary int
flammations during cardiopulmonary bypass (CPB).128 
Improved lung function and reduced mechanical ventit
lation requirements also have been reported following 
the use of leukoreduction in patients having abnort
mal preoperative pulmonary function.129t131 Recently 
two metatanalyses of 10 randomized, controlled trails 
evaluated the efficacy and effectiveness of RBC leukot
reduction and demonstrated that patients who were 
transfused leukoreduced RBCs might benefit from a 
decrease in postoperative infections. A decrease in mort
tality may have been realized if more patients had been 
enrolled in the various randomized trials.132
The results of a retrospective before/after study folt
lowing the institution of ULR in Canada compared 
cardiac surgery, hip fracture repair, and intensive care 
unit patients and found decreased mortality, fewer fever 
episodes, and subsequent use of antibiotics in hightrisk 
patients (Table 10).133 Subsequent reduced length of 
hospital stay and cost of hospital care may be an adt
ditional financial benefit.134,135 
TRIM and cancer. A higher rate of tumor growth 
and recurrence with allogenic transfusion and lower 
rates with leukoreduced ones have been reported in a 
number of experimental animal model studies.136,137 
Approximately 90 observational studies in man have 
examined the effect of TRIM on tumor growth prot
motion.138 Of these, 33 (30 observational and 3 rant
domized, controlled trials) have been in patients with 
a colorectal malignancy; 14 in patients with a head and 
neck malignancy; 10 in patients with a breast maligt
nancy; 8 in patients with a gastric malignancy and 8 in 
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Figure 2: randomized controlled trials (rCTs) conducted in cardiac surgery investigating the association of wbC-containing 
allogeneic blood transfusion with short-term (up to 3 months post transfusion) mortality from all causes.127 The odds ratio (Or) of short-
term mortality in recipients of non-wbC-reduced versus wbC-reduced allogeneic rbCs, is shown. These Ors are calculated  from 
intention-to-treat analysis. The figure also shows the summary Ors of short-term mortality across the depicted rCTs, as calculated 
from a meta-analysis.110,119,121-123
Table 10. before-after study evaluating the effect of the implementation of universal leukoreduction on various primary and secondary 
outcomes in 14 786 patients.79
Leukoreduction (%) 
(n=7804)
Non-leukoreduction (%) 
(n=6983)
Odds ratio (95% 
confidence interval) P Value
Primary outcomes
in-hospital mortality 6.19 7.03 0.87 (0.76-1.00) .04
Suspected infections 12.7 13.9 0.91 (0.83-1.00) .05
Confirmed infections 10.1 10.7 0.93 (0.84-1.04) .21
Secondary outcomes
respiratory failure 9.6 10.1 0.94 (0.84-1.05) .30
Hemodynamic failure 1.9 1.9 1.02 (0.80-1.13) .93
renal failure 1.0 1.1 0.93 (0.67-1.30) .72
Fever 22.5 24.7 0.88 (0.82-0.95) <.01
Antibiotic use 14.8 16.4 0.89 (0.81-0.97) <.01
Transfusion reactions 0.46 0.64 0.71 (0.45-1.13) .16
Favors leukoreduction
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patients with a lung malignancy. Approximately 50% 
of the available observational studies (level 3 evidence) 
indicate that patients having allogeneic transfusions 
(compared with those not having such transfusions) 
had a higher incidence of cancer recurrence or death as 
a result of cancer recurrence as well as a shorter overall 
survival after the cancer resection operation.138t141
 The three randomized, controlled trials in colorectal 
cancer patients that compared the incidence of cancer 
recurrence in recipients of buffy coattreduced allogeneic 
RBCs with that of recipients of control blood, showed 
no statistical difference in the incidence of cancer ret
currence.106,109,116 The randomized, controlled trials 
in human are thus still inconclusive. This may be due 
to the lack of homogeneity among the studies, the dift
ference in blood component preparation used (buffy 
coat method versus leukofiltration), multicenter versus 
single center trials and the type of data analysis by int
vestigators (multivariate versus univariate). Studies in a 
rabbit allogenic transfusion tumor growth model clearly 
indicated that buffy coat reduction was associated with 
a significant reduction in pulmonary tumor nodule fort
mation.142,143
Transfusion-associated graft-versus-host-disease 
(TA-GVHD)
TAtGVHD is an infrequent, although almost uniformt
ly fatal complication of blood transfusion, caused by a 
proliferation of Ttcell lymphocytes derived from the dot
nor. Patients with celltmediated immunodeficiency are 
at particular risk for TAtGVHD. Another risk group 
includes patients who have an HLA genotype that is 
haploidentical with that of the donor.144 No studies ext
ist investigating the efficacy of leukoreduction for the 
prevention of TAtGVHD. There are only single case 
reports and animal studies.145 These reports conclude 
that the minimum threshold of transfused lymphot
cytes which prevents the development of TAtGVHD 
cannot currently be defined.146t148 A very recent report 
describes a reduction in reports of TAtGVHD to the 
United Kingdom Serious Hazards Of Transfusion 
Program (UK SHOT) since the introduction of ULR 
in the UK (11 reports of GVHD associated with nont
leukoreduced blood components, and only two with the 
use of leukoreduced blood components). This low rate 
has occurred with the use of a combination of ULR and 
the provision of gammatirradiated blood components 
for patients at risk.149 The gammatirradiation of blood 
components has been demonstrated as the best current 
technology to reduce the risk of TAtGVHD.150 In any 
event, most patients who need gammatirradiated blood 
components also should receive leukoreduced blood 
components as well. Both measures simultaneously apt
plied in order to prevent TAtGVHD will result in the 
increased safety of allogeneic transfusions. Another apt
proach might be the use of pathogen inactivation.151This 
report also describes a reduction in cases of postttranst
fusion purpura (PTP) following the introduction of 
ULR (mean number of reports/year before ULR 10.3; 
post ULR 2.3).149
Transfusion-related acute lung injury (TRALI)
TRALI is a severe, often fatal, and complex complication 
of transfusion. TRALI has become the most common 
cause of transfusiontassociated mortality reported to 
both the United States Food and Drug Administration 
(US FDA) and UK SHOT.14,15,151 Although the pathot
physiology of TRALI is not well understood,152 sevt
eral mechanisms for TRALI have been postulated: 
Popovsky’s immunetmediated model,153 in which donor 
antibodies and less frequently recipient antibodies caust
ing an immune reaction targeting leukocyte antigens 
and Silliman’s twothit model.154 In the latter model, the 
first hit is a physiological insult that activates pulmot
nary endothelium and promotes priming, resulting in 
the adhesion of neutrophils, (sepsis and trauma). The 
second hit is an event that activates the neutrophils, 
causing the release of biological active mediators present 
in the blood components.155 If Silliman’s model is valid, 
pretstorage leukocyte filtration and the use of younger 
blood components in attrisk patients should reduce the 
incidence of TRALI. Leukoreduction reduces biologit
cally active mediators associated with prolonged stort
age,154t158 but whether leukoreduction can reduce the 
incidence of TRALI is not currently known. 
Current international status of ULR
Internationally, 19 countries (Table 11) have implet
mented ULR as part of their blood safety policy. Several 
other countries are also currently moving toward imt
plementing ULR, including Sweden, Denmark, Italy, 
Belgium, Cyprus and Japan.159 The motivation to implet
ment ULR varies from one country to another. Some 
countries, including the United Kingdom and Portugal, 
decided to adapt ULR in an effort to comply with the 
precautionary principle concerning the theoretical risk 
of TAtvCJD.160 This decision was taken because of 
evidence that indicated that the pathogenic prion, the 
causative agent of vCJD, was associated with Btlymt
phocytes. The precautionary principle calls for reducing 
potential serious risks to public health even if cause and 
effect relationships are not fully established scientifit
cally. Other countries, such as Germany and Canada, 
have relied on the evidence of clinical benefit in other 
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Table 11. Countries that have mandated universal leukocyte 
reduction as a matter of public blood safety policy. 
Country Date
France April 1998
Canada July 1998 (platelets only)
luxembourg December 1998
Austria January 1999
eire (Southern ireland) January 1999
Canada July 1999, ulr
wales August 1999
Scotland August 1999
Switzerland September 1999
england October 1999
northern ireland October 1999
Malta January 2001
Spain (portugal) May 2001
new Zealand June 2001
united Arab emirates July 2001
Germany October 2001
Qatar January 2002
Holland January 2002
norway January 2002
Finland november 2002
ulr=universal leukocyte reduction, platelets and rbCs.
clinical areas to justify the adoption of ULR for all 
transfused patients. In some countries, such as Canada, 
blood safety is considered paramount, and the use of 
safer blood components, such as those that are leukot
cyte reduced cannot be restricted and must be applied 
to all patients.161
The adoption of ULR in the United States has been 
delayed primarily because of economic issues, leading to 
the approach of selective leukocyte reduction protocols 
for patients thought to be at greatest risk for adverse 
effects associated with the presence of leukocytes in 
blood components. The selective patient populations 
include those who are immunocompromised or chronit
cally transfused. The welltestablished leukocyte medit
ated reactions include febrile reactions (fever), alloimt
munization and its clinically significant consequence 
known as platelet refractoriness, and transfusion transt
mitted leukocyte associated viruses such as CMV. The 
differences in practice, belief, and opinion on how best 
to spend money for blood components has formed 
the basis for the controversy in the United States over 
ULR. Both the FDA blood product advisory committ
tee (BPAC) in 1998 and the blood safety and availabilt
ity (BSAC) in 2001 recommended ULR for the United 
States blood supply.162,163 
 Both the additional cost of ULR and the controversy 
over the available clinical evidence to support the use of 
leukoreduction for all patients has delayed implementat
tion of ULR in the United States, despite the BPAC 
and BSAC recommendations. In fact, the ULR debate 
has become so politicized that it has become one of the 
most divisive issues in the history of US transfusion 
medicine. In 2005, approximately 65% to 70% of the 
blood supply was leukocyte reduced in the US.161 It is 
important to note in this context that many centers and 
hospitals in the US provide ULR blood components.
At present ULR is practiced in only approximately 
20 countries. The main reason for not implementing 
ULR universally appears to be financial. Other reasons 
include the opinion that there is not yet sufficient evit
dence to justify adopting the policy of ULR.164,165 
International experience
Hebert et al133 evaluated clinical outcomes after the 
adoption of ULR in Canada by conducting a retrot
spective before and after cohort study in 23 academic 
and community hospitals (n=14 786). Although an 
increased risk of nosocomial infections was not demont
strated in this trial, inthospital mortality was found to 
be significantly lower (P=.04) following the introduct
tion of ULR in Canada.133 The authors of this study 
indicate that assuming a 7% mortality rate in the cont
trol period, the decreased odds of death based on these 
results would translate to one life saved for every 120 
patients who received leukocyte reduced blood as opt
posed to nontleukoreduced blood. This observation, 
according to the authors, was consistent among all subt
groups and throughout the range of blood exposures. In 
addition, this study also found that ULR was associated 
with a decreased frequency of febrile episodes and subt
sequent use of antibiotics.133
Fergusson et al166 evaluated the clinical outcome folt
lowing implementation of a ULR program in premat
ture infants admitted to neonatal intensive care units 
(NICUs) by conducting a retrospective before and aft
ter study in three Canadian tertiary care NICUs from 
January 1998 to December 2000. Thus study demont
strated no significant reduction in NICU mortality or 
bacteremia, but reported an improvement in several 
clinical outcomes in premature infants requiring RBC 
transfusions (Table 12).166 The authors therefore rect
ommended the adoption of ULR in the care of all low 
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Table 12. Outcomes and odds ratios among 515 premature infants who underwent transfusion before and after implementation of ulr 
in Canada.166
Outcomes*
Odds Ration (95% confidence interval)†
Non-leukoreduction period Post-leukoreduction period Adjusted‡
Primary outcomes
   bacteremia 79 (29.6) 63 (25.6) 0.59 (0.34-1.01)
   Mortality 45 (16.8) 44 (17.8) 1.22 (0.59-2.50)
Major NICU morbidities
   retinopathy of prematurity 130 (59.1) 96 (41.7) 0.56 (0.33-0.93)
   bronchopulmonary dysplasia 141 (52.6) 86 (34.8) 0.42 (0.25-0.70)
   necrotizing enterocolitis 32 (12.5) 16 (6.7) 0.39 (0.17-0.90)
   Grade 3 or 4 iVH 45 (17.4) 33 (13.7) 0.65 (0.35-1.19)
   Any major niCu morbidity§ 207 (83.5) 157 (66.5) 0.31 90.17-0.56)
Abbreviations: iVH, intraventricular hemorrhage; niCu, neonatal intensive care unit; ulr, universal leukoreduction. * All outcomes data are expressed as no. (%). Denominators 
vary from 268 and 247 because of missing data. †Odds ratios of less than 1.00 indicate a beneficial effect of leukoreduction. ‡All multivariate models included site, admission status 
(outborn/inborn), gestational age, sex, birth weight, mode of delivery, antenatal steroids, volume transfused, apgar score at 5 minutes, score for neonatal Acute physiology on day 
1, any cardiovascular pressor on day 1, continuous positive airway pressure, (0, 1-10. 11-25, or >25 days), influenza season (December-March), mechanical ventilation on day 1, 
high-frequency ventilation on day 1, supplemental oxygen support on day 1, surfactant use on day 1, steroids on day 1, umbilical catheter, and percutaneous catheter, § including 
retinopathy of prematurity, bronchopulmonary dysplasia, necrotizing enterocolitis, and grade 3 or 4 iVH.
birth weight infants requiring RBC transfusions.
 Another before and after study (n=2095), conductt
ed in the United Kingdom by Llewelyn et al167 examt
ined 11 hospitals with patients undergoing cardiac byt
pass surgery or total hip and/or knee replacement and 
found no impact of ULR on postoperative infections, 
as reported in the Canadian study, but this study was 
considerably smaller than the Canadian study (n=2095 
versus n=14 786). 
 Yazer et al,51 Paglino et al50 and King et al52 demt
onstrated that hospitals moving from a selective prot
tocol to ULR had a significantly reduced rate of fevers 
associated with RBC and platelet transfusions. These 
fevers occurred in patients who would have been unt
likely to receive leukocyte reduced blood with a select
tive protocol. The difficulty in conducting such studies 
will increase over time because there are few European 
countries that do not currently use ULR and because 
approximately 70% of the blood in the United States 
is already leukocyte reduced. Finding study sites which 
will also have a parallel and appropriate control arm to 
receive nontleukocyte reduced blood is becoming int
creasingly difficult.
Conclusions
The ongoing development of safer transfusion options 
for use in the care of patients has created many cont
troversies for the field of transfusion medicine. In the 
debate concerning the implementation of ULR, some 
experts believe that the clinical benefit for ULR has 
been shown for many potential recipients who suggest 
therefore that this technology be applied universally, as 
the only downside is cost.168 Others argue that in the 
absence of data suggesting universal benefit, the techt
nology should be applied only selectively to patients 
who will clearly benefit.165 
 All the data presented in this review clearly indicate 
that leukoreduction is associated with a reduced risk to 
patients for some clinical indications, but not for others. 
In some instances the available evidence is quite strong, 
but in others the evidence for instituting ULR is not 
as strong. It is nonetheless clear that ULR does reduce 
the risk and severity of NHFTRs (level 1 evidence), the 
risk of CMV transmission (level 1 evidence), and is ast
sociated with a reduced risk of HLA alloimmunization 
and platelet refractoriness (level 1 evidence). A causal 
relationship between allogeneic blood transfusions and 
cancer recurrence seems to be indicated by the obsert
vational studies (level 3 evidence) reported between 
1985 and 2000 but not by the available randomized, 
controlled trials in colorectal cancer patients (level 1 
evidence). Specifically, the three available randomized, 
controlled trials provide no indication that perioperat
tive allogeneic blood transfusion causes an increase in 
cancer recurrence or death as a result of cancer recurt
rence. Relevant experimental animal studies nonethet
less indicate that allogenic blood transfusions enhance 
tumor growth promotion in animal models. Concerning 
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whether leukoreduction is associated with a decreased 
incidence of preoperative mortality and postoperative 
infections, there is evidence, particularly in patients 
undergoing cardiac surgery,125 that the use of leukoret
duced blood components is associated with a decreased 
risk for bacterial infection (level 1 evidence); reduces the 
risk of multitorgan dysfunction (level 3 evidence); and 
most importantly leukoreduction significantly reduces 
the risk of mortality (level 1 evidence in cardiac surgery 
patients).125,127 
 Some have noted that there are significant problems 
with the use of selective transfusion protocols. One 
problem involves the selection of a patient who might 
meet the criteria for the selective use of leukoreduction, 
but who is not being recognized. Such patients thus do 
not get the best blood component and thus will not bent
efit from this intervention. This could result from phyt
sician ignorance, incomplete hospital databases, or pat
tients undergoing allogeneic transfusions at sites where 
leukoreduced blood components are not provided.169
What about female patients with multiple pregnant
cies? Transfusion with nontleukocyte reduced blood 
will likely further alloimmunize them. Does this then 
represent the mortgaging of their medical future? For 
example, if certain treatments might be required by 
such patients, such as kidney allograft transplantation, 
or the need for chemotherapy to manage a malignancy 
for which transfusion therapy support might be ret
quired?161
It seems illogical to support laboratorytbased prot
grams of quality management to reduce the errors and 
accidents affecting blood transfusion recipients without 
recognizing that selective transfusion programs are a 
major source of error. Thus, the implementation of good 
manufacturing practices and quality initiatives in blood 
centers and transfusion services will be inherently int
complete until they can assure that transfusion requiret
ments can be met without error.170
 In discussing public policy considerations, Vamvakis, 
Dzik and Blajchman stated the following: “In the abt
sence of considerations of cost, there is both scientific 
and medical consensus that leukocyte reduction is apt
propriate medical practice. The WBCs are not a comt
ponent of blood generally intended to be transfused 
and they can be viewed as undesirable. Furthermore, 
leukoreduction is almost entirely risk free at least in 
most situations”.170
Blajchman ended his 1999 editorial by quoting Sir 
Anthony Bradford Hill,168 the father of randomized 
controlled trials: “All scientific work is incomplete, 
whether it is observational or experimental. All scient
tific work is liable to be upset or modified by advancing 
knowledge. This does not confer on us a freedom to igt
nore the knowledge we already have, or to postpone the 
action that it appears to demand at a given time”.171
 If zero risk is the goal of transfusion medicine, the 
legacy from the HIV/HCV experience over the last two 
decades dictates that all risks should be considered and 
the resources allocated for each according to priority 
goals. As important as the direct financial cost is the post
sibility of retdirection of resources away from risks that 
have already been documented. In this regard it is imt
portant to note that most early manufacturing intervent
tions or changes in practice in transfusion medicine were 
not introduced based on quality of evidence! Moreover 
ULR should also be seen as an important processing 
step that will contribute to improving the safety and 
purity of blood components. In addition, it can also be 
seen as an important but necessary preliminary processt
ing step both resulting in safer products for transfusion 
recipients, but also one that will be required in anticipat
tion of the next new paradigm in transfusion medicine: 
pathogen inactivation (see Table 1).172 
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